Commonwealth Equity Services LLC lessened its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 598,326 shares of the healthcare product maker's stock after selling 30,754 shares during the quarter. Commonwealth Equity Services LLC's holdings in Abbott Laboratories were worth $59,133,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp grew its position in Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. Bank of America Corp DE acquired a new position in Abbott Laboratories in the 2nd quarter valued at approximately $1,603,607,000. Deutsche Bank AG increased its stake in Abbott Laboratories by 18.6% in the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock valued at $1,515,963,000 after buying an additional 2,614,965 shares during the period. Finally, Legal & General Group Plc purchased a new stake in Abbott Laboratories in the 2nd quarter worth approximately $1,082,524,000. Institutional investors and hedge funds own 75.18% of the company's stock.
Insider Activity
In related news, EVP Mary Moreland sold 3,500 shares of the company's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the sale, the executive vice president directly owned 100,791 shares in the company, valued at approximately $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.46% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on ABT. Wells Fargo & Company lifted their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an "overweight" rating in a research note on Thursday, October 22nd. Robert W. Baird upped their price target on shares of Abbott Laboratories from $121.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday, October 22nd. Citigroup cut their price objective on Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating for the company in a report on Thursday, October 22nd. Rothschild & Co Redburn raised Abbott Laboratories from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Finally, Argus downgraded Abbott Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $118.32.
Check Out Our Latest Research Report on Abbott Laboratories
Abbott Laboratories Price Performance
Shares of ABT opened at $110.02 on Friday. The firm has a market cap of $190.38 billion, a PE ratio of 41.05, a PEG ratio of 1.93 and a beta of 0.54. The firm's 50 day moving average price is $104.04 and its 200 day moving average price is $101.78. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.45. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02.
Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same period in the previous year, the firm posted $1.30 earnings per share. The company's revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's payout ratio is presently 94.03%.
Abbott Laboratories Profile
(
Free Report)
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings.
Abbott's offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.